• 

  August 29, 2025

  Immune Checkpoint Inhibitor Side Effects & Toxicity More Common Than Reported

  Charles H. Weaver, MD

• 

  August 28, 2025

  Treatment of Stage 0 & I “Superficial” Bladder Cancer

  Charles H. Weaver, MD

• 

  August 24, 2025

  Precision Cancer Medicines for Colon Cancer

  Charles H. Weaver, MD

• 

  August 3, 2025

  Treatment of Stage IV-Metastatic Cervical Cancer

  Charles H. Weaver, MD

• 

  April 10, 2025

  Tissue Agnostic – Genomic Based Treatment – A Paradigm Shift in Cancer Treatment

  Charles H. Weaver, MD

• 

  January 7, 2025

  FDA Approves Subcutaneous Immunotherapy

  Charles H. Weaver, MD

• 

  April 11, 2024

  Checkpoint Inhibitor – Chemotherapy for Treatment of Small Cell Lung Cancer

  Charles H. Weaver, MD

• 

  March 14, 2024

  Checkpoint Inhibitor Immunotherapy for Treatment of Advanced Cervical Cancer

  Charles H. Weaver, MD

• 

  October 24, 2023

  Keytruda & Other Checkpoint Inhibitors for Triple Negative Breast Cancer

  Charles H. Weaver, MD

• 

  October 16, 2023

  Treatment of Stage II Melanoma

  Charles H. Weaver, MD

• 

  September 1, 2023

  Ask The Experts About ctDNA Surveillance Monitoring-Changing the Management of Melanoma

  Charles H. Weaver, MD

• 

  April 25, 2023

  Keytruda® PD-1 Immunotherapy Treatment Improves Survival in Melanoma

  Charles H. Weaver, MD